TABLE 2

Treatments on the horizon for myasthenia gravis

Complement inhibitor
Zilucoplan
Neonatal Fc receptor inhibitors
Batoclimab
Nipocalimab
Rozanolixizumab
B-lymphocyte depletion therapy
Obinutuzumab
Ofatumumab
Ublituximab
Blinatumomab
Inebilizumab
Cytokine inhibitor
Tocilizumab
Janus kinase inhibitors
Ruxolitinib
Baricitinib
Tofacitinib
Hematopoietic stem cell transplantation
Chimeric antigen receptor T-cell therapy